Clinerion Expands in Poland
EMC Szpitale augments Clinerion’s patient coverage in Poland by joining the Patient Network Explorer platform. Patients at the hospital group will gain access to clinical trials, and actively support the launch of medical treatments.
Joining Clinerion’s hospital partner network gives EMC Spitale visibility to trial sponsors on their readiness to participate in clinical research on an international level. EMC Szpitale patients will gain access to clinical care as the Patient Network Explorer draws international clinical studies to the hospital group, directly to the patients.
EMC Szpitale operates 11 hospitals and 19 outpatient clinics, providing primary and specialized medical care to over one million patients across Poland. EMC Szpitale specializations include advanced diagnostics to comprehensive hospital treatment in gastroenterology, rehabilitation, urology, orthopedics, general surgery, gynecology, obstetrics and geriatric care. Currently, the hospital group is running 37 different clinical trials.
EMC Szpitale uses an artificial intelligence technology supporting oncologists in choosing optimal cancer treatments. With their focus on geriatric care, EMC Szpitale is a partner of the nationwide social campaign ‘Understand Old Age’. The hospital group pioneers innovative ways of thinking and operational processes. The implementation of Lean Management at the hospital in Lubin has been recognized with the award for the Innovative Hospital 2017 in the Success of the Year in Healthcare competition.
“We care for our patients. Everyday. In a better way. That’s why we work to increase interest and enrollment in clinical trials to ultimately ensure greater availability of innovative therapies for our patients,” says Anna Szewczuk-Lebska, spokesperson for EMC Szpitale.
“Sponsors are looking for trials sites with the highest levels of care, therapeutic experience and clinical experts,” says Ian Rentsch, Clinerion CEO. “EMC Spitale’s broad therapeutic coverage and geographical situation make it a great partner for them and for Clinerion.”
To learn more go to www.clinerion.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
